MX350463B - Métodos de tratamiento del dolor. - Google Patents

Métodos de tratamiento del dolor.

Info

Publication number
MX350463B
MX350463B MX2014000744A MX2014000744A MX350463B MX 350463 B MX350463 B MX 350463B MX 2014000744 A MX2014000744 A MX 2014000744A MX 2014000744 A MX2014000744 A MX 2014000744A MX 350463 B MX350463 B MX 350463B
Authority
MX
Mexico
Prior art keywords
methods
treating pain
directed
subject matter
disclosed subject
Prior art date
Application number
MX2014000744A
Other languages
English (en)
Other versions
MX2014000744A (es
Inventor
Daniel B Carr
Peter Lacouture
Garcia De Rocha Marcelo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of MX2014000744A publication Critical patent/MX2014000744A/es
Publication of MX350463B publication Critical patent/MX350463B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La materia actualmente divulgada está dirigida a métodos para tratar dolor post-operatorio administrando una combinación de una dosis aprobada de inferior a mínima de diclofenaco y beta-ciclodextrina; la materia actualmente divulgada también está dirigida a métodos para tratar el dolor en mamíferos de alto riesgo u obesos que necesitan analgesia.
MX2014000744A 2011-07-20 2012-07-19 Métodos de tratamiento del dolor. MX350463B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509886P 2011-07-20 2011-07-20
PCT/US2012/047453 WO2013013076A1 (en) 2011-07-20 2012-07-19 Methods of treating pain

Publications (2)

Publication Number Publication Date
MX2014000744A MX2014000744A (es) 2014-05-14
MX350463B true MX350463B (es) 2017-09-06

Family

ID=47558482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000744A MX350463B (es) 2011-07-20 2012-07-19 Métodos de tratamiento del dolor.

Country Status (16)

Country Link
US (1) US20140221490A1 (es)
EP (2) EP2734212B1 (es)
JP (2) JP6320917B2 (es)
KR (1) KR20140063583A (es)
CN (1) CN103781484A (es)
AU (1) AU2012283915B2 (es)
BR (1) BR112014001335A2 (es)
CA (1) CA2841964A1 (es)
DK (1) DK2734212T3 (es)
ES (1) ES2646226T3 (es)
IL (1) IL230433A0 (es)
IN (1) IN2014CN00315A (es)
MX (1) MX350463B (es)
MY (1) MY166036A (es)
NO (1) NO2854815T3 (es)
WO (1) WO2013013076A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
EP3018122B1 (en) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20180025116A1 (en) * 2016-07-22 2018-01-25 Arizona Board Of Regents On Behalf Of University Of Arizona Clinical Event Management and Communication System
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
AU2021208601A1 (en) * 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN111494446B (zh) * 2020-05-18 2021-08-17 深圳市宝安中医院(集团) 治疗胆绞痛的中药组合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
PL369966A1 (en) 2002-01-15 2005-05-02 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN1878711B (zh) * 2003-11-04 2010-12-22 奥蒂斯电梯公司 自动乘客输送机的低速运行
DE602004025151D1 (de) * 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
CN101264086A (zh) 2007-03-14 2008-09-17 南京师范大学 含有头孢克肟环糊精包合物的药物组合物及其制备方法
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US7662858B2 (en) * 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain

Also Published As

Publication number Publication date
JP2017110022A (ja) 2017-06-22
KR20140063583A (ko) 2014-05-27
CA2841964A1 (en) 2013-01-24
NO2854815T3 (es) 2018-04-21
AU2012283915B2 (en) 2016-11-24
WO2013013076A1 (en) 2013-01-24
EP3257505A1 (en) 2017-12-20
ES2646226T3 (es) 2017-12-12
CN103781484A (zh) 2014-05-07
IL230433A0 (en) 2014-03-31
US20140221490A1 (en) 2014-08-07
MY166036A (en) 2018-05-21
JP6320917B2 (ja) 2018-05-09
DK2734212T3 (da) 2017-11-06
AU2012283915A1 (en) 2014-02-06
MX2014000744A (es) 2014-05-14
EP2734212A1 (en) 2014-05-28
EP2734212A4 (en) 2014-12-24
JP2014520893A (ja) 2014-08-25
BR112014001335A2 (pt) 2017-02-21
EP2734212B1 (en) 2017-09-06
IN2014CN00315A (es) 2015-04-03

Similar Documents

Publication Publication Date Title
MX350463B (es) Métodos de tratamiento del dolor.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
IN2014KN00996A (es)
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
NZ705008A (en) Novel modulators and methods of use
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
NZ628433A (en) Chitosan-derived compositions
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
MX364220B (es) Metodos de tratamientos de fibrosis.
IN2014DN08385A (es)
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
IN2014CN02315A (es)
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.

Legal Events

Date Code Title Description
FG Grant or registration